Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last ...
ImmuneSensor begins patient dosing in phase 1 trial of lead cGAS inhibitor drug candidate, IMSB301 to treat inflammatory and autoimmune diseases: Dallas, Texas Thursday, October 1 ...